Search Results
Christopher Cannon, ADA 2020: Results of the Phase III VERTIS-CV Trial
Researcher comment: The VERTIS-CV trial | Chris Cannon
Christopher Cannon, MD: VERTIS-CV and Ertugliflozin
ADA 2020: Findings from EMPA-REG OUTCOME trial — Dr Muthiah Vaduganathan
Expert commentary: The VERTIS-CV trial | Francesco Giorgino
Christopher Cannon: Diabetes and Cardiovascular Disease.
Diabetes Newsflash (6/7/20) - No Proven Cardiovascular Risk Reduction with Steglatro
Chris Cannon, MD, Talks Trends in Cardiovascular Risk Prevention
Dr Christie Ballantyne Late Breaking Session at EAS Congress 2019
Cardiology Countdown | COURAGE, Health Literacy and STEMI Care
NSAID Risk, CIMT and 2011 Prevention Guidelines
Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder
